


# Bispecific Antibodies


MARKET & PIPELINE



**12**  
Marketed  
Bispecific antibodies



in **liquid tumor**  
indications




**bispecific T-cell engager**  
marketed



## Bispecific antibodies in development : active pipeline


Evolution of new clinical trials



Number of products in the clinical stages

**13** Pre-registration  
**34** Phase III  
**130** Phase II  
**210** Phase I

Top targets for pipeline products



Clinical innovation trends

